Evidence map›Paper›PMID 40093994›Full record

ArticleFrontiers in chemistry2025

Design, synthesis,

Elaheh Ataollahi, Leila Emami, Al-Anood Mohammad Al-Dies, Fateme Zare, Alireza Poustforoosh, Mina Emami, Fateme Saadat, Fateme Motamen, Zahra Rezaei, Soghra Khabnadideh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elaheh Ataollahi *Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Leila Emami *Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Al-Anood Mohammad Al-DiesDepartment of Chemistry, Al Qunfudah University College, UMM Al-Qura University, Mecca, Saudi Arabia.
Fateme ZarePharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Alireza PoustforooshMedicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mina EmamiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Fateme SaadatStudent Research Committee, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Fateme MotamenStudent Research Committee, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra RezaeiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Soghra KhabnadidehPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cancer is a complex group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. These cells can invade nearby tissues and organs, or they may metastasize to other parts of the body through the bloodstream or lymphatic system. Methods: In this study, eight novel pyrimidine-morpholine hybrides ( Results and discussion: It was demonstrated that all derivatives had appropriate cytotoxic potential with IC

Indexed as

cell cyclecytotoxicDNAmorpholinepyrimidinesimulationsynthesis

Identifiers

PMID40093994
PMCPMC11906455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.